Investor Presentaiton

Company overview Financial performance Oncology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Ophthalmology Neuroscience Respiratory Disease ecleralimab - TSLP inhibitor NCT04410523 (CCSJ117A12201C) Indication Asthma Phase Phase 2 Patients 625 Primary Outcome Measures Pre-dose FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment. Average change from baseline in pre- dose FEV1 at week 8 & week 12 CSJ117 0.5mg Arms Intervention CSJ117 1mg CSJ117 2 mg Target Patients CSJ117 4 mg CSJ117 8 mg Placebo Asthma patients on background medium or high ICS plus LABA therapy Read-out Milestone(s) 2023 Publication Primary publications planned for 2024 88 Investor Relations | Q2 2022 Results References Abbreviations Cardio-Renal Global Health Biosimilars NOVARTIS | Reimagining Medicine

View entire presentation